Cyclopharm (ASX:CYC) GF Value Rank: 10 (As of Jul. 12, 2026) — 67% Above Median


ASX:CYC Cyclopharm Ltd ASX:CYC
45 GF Score
Price A$0.53
GF Value A$0.83
Valuation Possible Value Trap
! 7 Warning Signs
View Full Analysis

What is Cyclopharm GF Value Rank?

Cyclopharm ASX:CYC +2.94% 45 GF Value Rank is 10 as of Jul. 12, 2026, which is 67% above its 10-year median of 6.00. GuruFocus rates ASX:CYC with a GF Score™ of 45/100 and a GF Value™ of A$0.83 (Possible Value Trap). The stock has 7 warning signs investors should review.

Cyclopharm has the GF Value Rank of 10.

GF Value Rank evaluates the exclusive GuruFocus valuation and performance of a stock, rated on a scale from 1 to 10. It is determined by the price-to-GF-Value (P/GF Value) ratio, a proprietary metric calculated based on historical multiples along with an adjustment factor based on a company's past returns and growth and future estimates of the business' performance.

GuruFocus found that for valuation, we cannot simply give stocks a better GF Value rank simply because they have a lower P/GF Value ratio. Backtesting shows that over the long term, the two worst-performing groups are the most expensive group (with the highest P/GF Value ratio) and the least expensive group (with the lowest P/GF Value ratio).

We can understand why the most expensive group underperforms. We were initially puzzled by the underperformance of the least expensive group, but we realized there is a reason why some stocks are super cheap. If they look too undervalued, it is often because the businesses behind them are poor quality. The market realized this and gave them low valuations. In a way, the market is efficient.

After multiple backtesting analyses, we granted the stocks in third-cheapest percentile the highest GF Value rank, as they have performed the best over a full market cycle. Stock performance is actually not as sensitive to valuation as it is to growth and profitability. On average, the companies in the 20%-50% valuation groups have similar performances. Therefore, we should avoid the most expensive and the least expensive stocks. We can be more tolerant of valuation.

A higher score indicates a stock with a relatively low valuation and substantial potential for outperformance. Conversely, a lower score often reflects stocks that are either highly overvalued or deeply undervalued, both of which tend to underperform.

Please click GF Score to see more details on the GF Score's 5 Key Aspects of Analysis.


ASX:CYC vs MCK, CAH, COR: GF Value Rank Comparison

For the Medical Distribution subindustry, Cyclopharm's GF Value Rank, along with its competitors' market caps and GF Value Rank data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Cyclopharm GF Value Rank vs Medical Distribution Industry

For the Medical Distribution industry and Healthcare sector, Cyclopharm's GF Value Rank distribution charts can be found below:

* The bar in red indicates where Cyclopharm's GF Value Rank falls into.


ASX:CYC
45GF Score
Cyclopharm Ltd ASX:CYC
GF Value Rank is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
Frequently Asked Questions Learn more about GF Value Rank →
What does a GF Value Rank of 10 mean?
Cyclopharm (ASX:CYC) has a GF Value Rank of 10 as of Jul. 12, 2026. GF Value Rank is given based on historical multiples along with past returns, growth and future estimates of the business' performance. View historical data on Cyclopharm and its competitors. This is 67% above median its historical median of 6.00. Over the past decade, Cyclopharm's GF Value Rank has ranged from 1.00 to 10.00.
Is Cyclopharm's GF Value Rank too high?
Cyclopharm's current GF Value Rank of 10 is 67% above median its 10-year median of 6.00. Over the past 10 years, this metric has ranged from a low of 1.00 to a high of 10.00. Overall, Cyclopharm has a GF Score™ of 45/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Cyclopharm's GF Value Rank compare to MCK and CAH?
Cyclopharm's GF Value Rank of 10 can be compared against companies in the Medical Distribution industry. Historically, Cyclopharm's own GF Value Rank has ranged from 1.00 to 10.00 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good GF Value Rank for a Medical Distribution company?
A good GF Value Rank depends on the Medical Distribution industry context. However, GF Value Rank should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high GF Value Rank mean?
A high GF Value Rank can signal that a stock is expensive relative to its fundamentals. GF Value Rank is given based on historical multiples along with past returns, growth and future estimates of the business' performance. View historical data on Cyclopharm and its competitors. Cyclopharm's current GF Value Rank is 10, which is 67% above median its own 10-year median of 6.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Cyclopharm stock overvalued right now?
Based on GuruFocus' analysis, Cyclopharm (ASX:CYC) is currently considered Possible Value Trap. The stock's GF Value™ is A$0.83, compared to a current price of A$0.53 — trading 36.7% below its estimated fair value. The current GF Value Rank is 10, which is 67% above median its 10-year median of 6.00. Cyclopharm's overall GF Score™ is 45/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is GF Value Rank calculated?
GF Value Rank is calculated from a company's financial statements. For Cyclopharm (ASX:CYC), the current GF Value Rank is 10 as of Jul. 12, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Cyclopharm (ASX:CYC) Overvalued in 2026?

Based on GuruFocus' analysis, Cyclopharm stock appears to be undervalued. The current stock price of A$0.53 is trading 36.7% below its estimated GF Value™ of A$0.83. GuruFocus considers Cyclopharm to be Possible Value Trap.

Key valuation signals for ASX:CYC:

  • GF Value Rank: 10 (67% above median its 10-year median of 6.00)
  • GF Value™: A$0.83 vs. price of A$0.53 (36.7% below fair value)
  • GF Score™: 45/100 with 7 warning signs

No single metric tells the full story. See the ASX:CYC stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Cyclopharm Business Description

Address 1 The Crescent, Unit 4, Kingsgrove, Sydney, NSW, AUS, 2208
Cyclopharm Ltd is a health technology company offering solutions related to functional lung ventilation imaging. Its proprietary product Technegas is a broad-spectrum diagnostic lung imaging technology product for the visualisation of pulmonary ventilation and lung function. The company sells its products to healthcare institutions and medical professionals. Maximum revenue is generated from its Technegas products and services, which include the sale of diagnostic equipment and consumables used by physicians in the detection of pulmonary embolism and other respiratory conditions. Geographically, the company generates maximum revenue from its business in Europe, and the rest from Asia Pacific, Canada, the USA, and other regions.
45GF Score

Get the complete analysis for ASX:CYC

GF Value Rank is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

A$0.53
Price
A$0.83
GF Value